Catégorie : Publications récentes

Cannabis à usage médical : la France saura-t-elle combler son retard ?, Bertrand Lebeau Leibovici, juin 2019

Cannabis à usage médical : la France saura-t-elle combler son retard ? Bertrand Lebeau Leibovici Médecin addictologue Membre fondateur du GRECC  Juin 2019   Agnès Buzin réussira-t-elle là où Bernard Kouchner puis Marisole Touraine ont échoué ? En queue de peloton européen sur la question de l’accès au cannabis à usage thérapeutique, la France, reconnait l’actuelle ministre de la Santé, a pris du « retard ». Pour le rattraper, elle a demandé à l’Agence Nationale de Sécurité du Médicament (ANSM) de créer un Comité Scientifique Spécialisé Temporaire (CSST) présidé par le professeur Nicolas Authier, qui dirige aussi la Commission des Stupéfiants et Psychotropes, dans le cadre de l’ANSM.   L’enfant chéri de l’Agence a [...]

Lire la suite

Therapeutic Prospects of Cannabidiol for Alcohol Use Disorder and Alcohol-Related Damages on the Liver and the Brain, Julia De Ternay et al., 2019,

Therapeutic Prospects of Cannabidiol for Alcohol Use Disorder and Alcohol-Related Damages on the Liver and the Brain Julia De Ternay, Mickaël Naassila Mikail Nourredine, Alexandre Louvet, François Bailly, Guillaume Sescousse, Pierre Maurage, Olivier Cottencin, Patrizia Maria Carrieri  and Benjamin Rolland Frontiers in Pharmacology, 2019, Volume 10, Article 627 doi : 10.3389/fphar.2019.00627 Abstract Background : Cannabidiol (CBD) is a natural component of cannabis that possesses a widespread and complex immunomodulatory, antioxidant, anxiolytic, and antiepileptic properties. Much experimental data suggest that CBD could be used for various purposes in alcohol use disorder (AUD) and alcohol-related damage on the brain and the liver. Aim : To provide a rationale for [...]

Lire la suite

Ayahuasca : Uses, Phytochemical and Biological Activities, Edgar Antonio Estrella‑Parra et al., 2019

Ayahuasca : Uses, Phytochemical and Biological Activities Edgar Antonio Estrella‑Parra, · Julio Cesar Almanza‑Pérez, · Francisco Javier Alarcón‑Aguilar Natural Products and Bioprospecting, 2019 https://doi.org/10.1007/s13659-019-0210-5 Abstract Ayahuasca (caapi, yajé), is a psychoactive brew from the Amazon Basin region of South America traditionally considered a “master plant.” It is prepared as a decoction from Banisteriopsis caapi and Psychotria viridis, which it is thought that it stimulates creative thinking and visual creativity. Native healers of the Orinoco and Amazon basins have used traditionally ayahuasca as a healing tool for multiple purposes, particularly to treat psychological disorders in the patients, with some beneficial effects experimentally and clinically validated. Recently, [...]

Lire la suite

Association between medical cannabis laws and opioid overdose mortality has reversed over time, Chelsea L. Shover et al., 2019

Association between medical cannabis laws and opioid overdose mortality has reversed over time Chelsea L. Shover, Corey S. Davis, Sanford C. Gordon, and Keith Humphreys PNAS, mai 2019 www.pnas.org/cgi/doi/10.1073/pnas.1903434116   Abstract Medical cannabis has been touted as a solution to the US opioid overdose crisis since Bachhuber et al. [M. A. Bachhuber, B. Saloner, C. O. Cunningham, C. L. Barry, JAMA Intern. Med. 174, 1668–1673] found that from 1999 to 2010 states with medical cannabis laws experienced slower increases in opioid analgesic overdose mortality. That research received substantial attention in the scientific literature and popular press and served as a talking point for the cannabis industry [...]

Lire la suite

Medical Cannabis No Solution to the Opioid Crisis, Batya Swift Yasgur, 2019

Medical Cannabis No Solution to the Opioid Crisis Batya Swift Yasgur, MA, LSW Medscape Medical News, June 11, 2019 https://www.medscape.com/viewarticle/914256?nlid=130206_2052&src=WNL_mdplsnews_190614_mscpedit_psyc&uac=292598PZ&spon=12&impID=1994987&faf=1   Contrary to previous research and popular assumptions, legalization of, and broader access to, medical cannabis has not reduced opioid overdose death rates. A study at Stanford University in California showed no protective effect of medical cannabis. In fact, states that legalized medical cannabis actually experienced a 22.7% increase in opioid overdose deaths. "There has been an idea touted by people and the cannabis industry and everyone invested in finding solutions to the opioid crisis that passing cannabis laws is one way to do that," lead author [...]

Lire la suite

Study will test pot’s effects on infants’ brain development, Brian Donohue, UW Medicine School of Medecine, 2019

May 10, 2019 Study will test pot’s effects on infants’ brain development Researchers seek to isolate cannabis from concurrent use of alcohol, tobacco, and illicit drugs. Media Contact: Brian Donohue - 206.543.7856, bdonohue@uw.edu Kleinhans Lab MRI scans of infants’ brains are part of the evaluation to discern effects of prenatal marijuana exposure. UW Medicine researchers are recruiting pregnant women to study whether prenatal marijuana use – in the absence of alcohol, tobacco, and any illicit drug consumption – affects their infants’ brain development, cognitive and motor development, medical health, and social behavior. The “Moms + Marijuana” study is co-led by Drs. Natalia Kleinhans and Stephen Dager, radiologists at [...]

Lire la suite

Cannabis For Cancer-Related Symptoms (CAFCARS), ClinicalTrials.gov Identifier : NCT03948074, mai 2019

Cannabis For Cancer-Related Symptoms (CAFCARS) https://clinicaltrials.gov/ct2/show/NCT03948074?recrs=abdf&cond=cannabis&draw=2&rank=98 ClinicalTrials.gov Identifier: NCT03948074 Recruitment Status : Not yet recruiting First Posted : May 13, 2019 Last Update Posted : May 13, 2019 See Contacts and Locations Sponsor: Pippa Hawley Information provided by (Responsible Party): Pippa Hawley, British Columbia Cancer Agency Study Description Brief Summary: Clinical evidence is urgently needed to be able to advise patients on which cannabis-based products to take, or to avoid, in managing cancer-related symptoms. This trial was therefore designed to determine which cannabis extract combination (High THC-Low CBD, Low THC-High CBD, or Equal amounts of THC and CBD) is most effective at treating cancer related symptoms for each [...]

Lire la suite

Marijuana and fertility, Sara Ilnitsky & Stan Van Uum, 2019

Marijuana and fertility Sara Ilnitsky MD, Stan Van Uum MD Canadian Medical Association Journal, 2019 June 10, 191, 23, E638. doi : 10.1503/cmaj.181577 CMAJ Podcasts: author interview at https://soundcloud.com/cmajpodcasts/181577-five   1 Tetrahydrocannabinol acts on the endocannabinoid system, which is ubiquitous in reproductive tissues Tetrahydrocannabinol, the active ingredient in marijuana, is a lipophilic compound with a prolonged half-life of 20–36 hours.1 Tetrahydrocannabinol activates the cannabinoid receptors, which are part of the endogenous endocannabinoid system. This system is found in the hypothalamus, pituitary and internal reproductive organs in both sexes.2,3 2 Marijuana use can decrease sperm count Smoking marijuana more than once weekly in the preceding 3 months (n = 130/1215) [...]

Lire la suite

The Endocannabinoid System : A New Treatment Target for Obsessive Compulsive Disorder ?, Reilly R. Kayser et al., 2019

The Endocannabinoid System : A New Treatment Target for Obsessive Compulsive Disorder ? Reilly R. Kayser, Ivar Snorrason, Margaret Haney, Francis S. Lee, and H. Blair Simpson1 Cannabis and Cannabinoid Research, 2019, Volume 4, Number 2, Mary Ann Liebert, Inc. DOI: 10.1089/can.2018.0049   Abstract Introduction : Obsessive-compulsive disorder (OCD) is a disabling illness that is associated with significant functional impairment. Although evidence-based pharmacotherapies exist, currently available medications are ineffective in some patients and may cause intolerable side effects in others. There is an urgent need for new treatments. Discussion : A growing body of basic and clinical research has showed that the endocannabinoid system(ECS) plays a role in [...]

Lire la suite

Cannabis Companies Push F.D.A. to Ease Rules on CBD Products, Sheila Kaplan, The New York Time, May 31, 2019

Cannabis Companies Push F.D.A. to Ease Rules on CBD Products By Sheila Kaplan The New York Time, May 31, 2019 CBD products have exploded in recent years, and are so numerous and varied as to include cheese pizza and fruit smoothies, like at this restaurant in Fort Lauderdale, Fla.CreditJennifer Lett/South Florida Sun-Sentinel, via Associated Press Image CBD products have exploded in recent years, and are so numerous and varied as to include cheese pizza and fruit smoothies, like at this restaurant in Fort Lauderdale, Fla.CreditCreditJennifer Lett/South Florida Sun-Sentinel, via Associated Press     WASHINGTON — It was Hempy Pet CBD Soft Chews, Mile High Labs and Women Grow, [...]

Lire la suite